Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 13/20 | 0.36 |
| ▸ | BACE2 | Q9Y5Z0 | 7/20 | 0.36 |
| ▸ | PGR | P06401 | 7/20 | 0.36 |
| ▸ | AR | P10275 | 2/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.34 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10329063 | 0.91 | BACE1 (0.43) | BACE1BACE2 | |
| SCHEMBL10329949 | 0.86 | BACE1 (0.45) | BACE1BACE2 | |
| SCHEMBL10329998 | 0.85 | BACE1 (0.47) | BACE1BACE2 | |
| SCHEMBL10329060 | 0.84 | PGR (0.36) | BACE1BACE2PGRARNR3C1 | |
| SCHEMBL10329923 | 0.84 | BACE1 (0.36) | BACE1BACE2 | |
| SCHEMBL10329921 | 0.83 | BACE1 (0.47) | BACE1BACE2PGR | |
| SCHEMBL19033621 | 0.82 | BACE1 (0.37) | BACE1BACE2 | |
| SCHEMBL12721358 | 0.81 | BACE1 (0.43) | BACE1BACE2 | |
| SCHEMBL10329066 | 0.81 | BACE1 (0.49) | BACE1BACE2 | |
| SCHEMBL10329024 | 0.79 | BACE1 (0.45) | BACE1BACE2PGRARNR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120183563-A1 | IMINOTHIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS AND THEIR USE | MERCK SHARP & DOHME LLC | 2012-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120183563-A1 | IMINOTHIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS AND THEIR USE | BACE1, BACE2, APP | BACE1 1/4885BACE2 2/4885PGR 2244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.